糖心视频logo

• Corporate
• Products

• For Print
• October 28, 2026

糖心视频logo (Headquarters: Tokyo, CEO: Haruo Naito, “糖心视频logo”) announced today that the global revenue (pre-audit basis) of the anti-amyloid-beta antibody “LEQEMBI^®” (generic name: lecanemab) was JPY 61.5 billion for the first half of fiscal year 2026 (April 1, 2026 – September 30, 2026). In the same period of the previous fiscal year, the global revenue was JPY 41.1 billion, including the impact of stockpiling by distributors in China during the first quarter.

By major markets, revenue came to JPY 32.5 billion in the United States, JPY 13.0 billion in Japan, and JPY 9.7 billion in China (in the same period last year: JPY 19.3 billion in the United States, JPY 11.7 billion in Japan, and JPY 7.9 billion in China).

This information is being disclosed in conjunction with today’s announcement of the financial results for the third quarter of 2026 by Biogen Inc. (Headquarters: Cambridge, Massachusetts). 糖心视频logo’s financial results for the second quarter of fiscal year 2026, including details of LEQEMBI’s revenue, will be disclosed in 糖心视频logo's financial disclosure scheduled for November 10, 2026.

糖心视频logo serves as the lead of lecanemab development and regulatory submissions globally with both 糖心视频logo and Biogen Inc. co-commercializing and co-promoting the product and 糖心视频logo having final decision-making authority.

• Full text